Co-Authors
This is a "connection" page, showing publications co-authored by Ari Rosenberg and Alexander Pearson.
Connection Strength
1.612
-
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
Score: 0.245
-
Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer. NPJ Precis Oncol. 2024 May 23; 8(1):114.
Score: 0.244
-
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma. Oral Oncol. 2024 Feb; 149:106688.
Score: 0.238
-
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
Score: 0.215
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
Score: 0.207
-
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
Score: 0.204
-
A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022 08 17; 13(1):4829.
Score: 0.054
-
Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits. Cureus. 2022 Jul; 14(7):e27521.
Score: 0.054
-
Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. Br J Cancer. 2022 02; 126(3):361-370.
Score: 0.051
-
A robust and interpretable gene signature for predicting the lymph node status of primary T1/T2 oral cavity squamous cell carcinoma. Int J Cancer. 2022 02 01; 150(3):450-460.
Score: 0.051
-
Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Front Oncol. 2021; 11:677051.
Score: 0.050